Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10640535
APP PUB NO 20150225456A1
SERIAL NO

14403350

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AGENUS INC3 FORBES ROAD LEXINGTON MA 02421

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
English, Ann Michelle Palmyra, US 3 2
Hawkins, Oriana E Tuscola, US 8 12
Hilderbrand, William H Edmond, US 2 2
Hunt, Donald F Charlottesville, US 47 366
Norris, Andrew Palmyra, US 20 249
Shabanowitz, Jeffrey Charlottesville, US 26 123

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 5, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 5, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00